Herceptin Medicines
Links shared publicly online about this topic
Combination overcomes breast cancer resistance to herceptin
physorg.com — “Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine.” View full resource at physorg.com
Most Recently Shared on March 13, 2011 at 6:06 pm By:
PhysOrg Health News Health News
Combination overcomes breast cancer resistance to herceptin http://tw.physorg.com/219243699
Combination Overcomes Breast Cancer Resistance to Herceptin
newswise.com — “Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine.” View full resource at newswise.com
Most Recently Shared on March 13, 2011 at 6:20 pm By:
newswise Health Communicator and Health News
Combination Overcomes Breast Cancer Resistance to Herceptin: Breast cancer tumors take numerous paths to resist ... http://bit.ly/hpEMKj
Combination Overcomes Breast Cancer Resistance to Herceptin
newswise.com — “Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine.” View full resource at newswise.com
Most Recently Shared on March 13, 2011 at 6:40 pm By:
#health news: Combination Overcomes Breast Cancer Resistance to Herceptin: Breast cancer tumors take numerous pa... http://bit.ly/hnHIos
Herceptin Fights Breast Cancer - Cancer Information (Cancers, Symptoms, Treatment) on MedicineNet.com
medicinenet.com — “Information on many different cancers includes symptoms, cancer detection and prevention, and treatment options.” View full resource at medicinenet.com
Most Recently Shared on January 30, 2010 at 9:03 am By:
Herceptin Again Proves Mettle Against Breast Cancer Title: Herceptin Again Proves Mettle Against Breast CancerCategor.. http://bit.ly/cvNmap
Curcumin exhibits potential utility in the treatment of HER-2 overexpressed breast cancer. | GreenMedInfo | Article | Natural Medicine | Alternative Medicine | Integrative Medicine
greenmedinfo.com — “This article on GreenMedInfo.com concerns - The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin.” View full resource at greenmedinfo.com
Most Recently Shared on September 9, 2011 at 12:33 pm By:
Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs
sciencedaily.com — “Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research.” View full resource at sciencedaily.com
Most Recently Shared on November 20, 2010 at 6:09 am By:
Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs: Targeted cancer thera... http://bit.ly/clhQ3f
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways : Nature Medicine : Nature Publishing Group
nature.com — “This report uncovers that activation of Src lies downstream of multiple trastuzumab-resistance-driving pathways. The authors show that Src, a major mediator of PI3K and IGFR resistance pathways, also drives resistance caused by PTEN loss, revealing that Src is directly dephosphorylated by PTEN. Src inhibition can overcome de novo and acquired trastuzumab resistance, suggesting a potential therapeutic strategy broadly applicable in breast cancer.” View full resource at nature.com
Most Recently Shared on April 7, 2011 at 8:35 pm By:
westr Doctor, Health Social Media, and PhD
Trastuzumab/Herceptin resistance: all roads lead to SRC @NatureMedicine http://bit.ly/dGtgjk & http://bit.ly/hC4Mu6 #pm101 #breastcancer
Medical News: ESMO: New Agent Shows Promise in Advanced Breast CA - in Meeting Coverage, ESMO from MedPage Today
medpagetoday.com — “MILAN -- An investigational trastuzumab combination agent showed promise in the treatment of advanced breast cancer when compared with trastuzumab (Herceptin) plus docetaxel (Taxotere), researchers re” View full resource at medpagetoday.com
Most Recently Shared on October 8, 2010 at 9:19 pm By:
ESMO: New Agent Shows Promise in Advanced Breast CA (CME/CE) http://bit.ly/9uVeWx
Medical News: ESMO: Obesity Does Not Interfere with Trastuzumab Response - in Meeting Coverage, ESMO from MedPage Today
medpagetoday.com — “MILAN -- Obesity is known to be a risk factor for breast cancer and death in postmenopausal women -- but a small study found that obesity does not seem to hamper the response to trastuzumab (Herceptin” View full resource at medpagetoday.com
Most Recently Shared on October 11, 2010 at 12:27 am By:
Drugs and Devices OW OW Health
ESMO: Obesity Does Not Interfere with Trastuzumab Response: MILAN -- Obesity is known to be a risk factor for... http://bit.ly/cBMMRS #drug
Medical News: ESMO: Older Women Too Can Benefit from Trastuzumab - in Meeting Coverage, ESMO from MedPage Today
medpagetoday.com — “MILAN -- Women in their 70s and 80s diagnosed with metastatic breast cancer appear to benefit from treatment with trastuzumab (Herceptin), researchers reported here.” View full resource at medpagetoday.com
Most Recently Shared on October 10, 2010 at 10:19 am By:
Drugs and Devices OW OW Health
ESMO: Older Women Too Can Benefit from Trastuzumab: MILAN -- Women in their 70s and 80s diagnosed with metast... http://bit.ly/ayckvC #drug
Medical News: Benefit, Cost at Odds in Gastric CA - in Oncology/Hematology, Other Cancers from MedPage Today
medpagetoday.com — “Patients with advanced gastric cancer lived about three months longer when trastuzumab (Herceptin) was added to conventional chemotherapy, investigators in a multinational trial reported.” View full resource at medpagetoday.com
Most Recently Shared on August 20, 2010 at 9:37 pm By:
Benefit, Cost at Odds in Gastric CA (CME/CE) http://bit.ly/bQszcE
Medical News: MBCS: Trastuzumab Costliest Advanced Breast Cancer Tx - in Meeting Coverage, MBCS from MedPage Today
medpagetoday.com — “SAN FRANCISCO -- Regimens that contain trastuzumab (Herceptin) are the most expensive in the metastatic breast cancer armamentarium, industry researchers found.” View full resource at medpagetoday.com
Most Recently Shared on September 19, 2011 at 9:26 pm By:
Roger D. Jones, PhD PhD, Doctor, Health Executive, and Health Social Media
Medical News: MBCS: Trastuzumab Costliest Advanced Breast Cancer Tx - http://t.co/LT3rVoD0 from @medpagetoday #health #medicine
Medical News: SABCS: No Cognitive Decline from Radiation to Prevent Brain Mets - in Meeting Coverage, SABCS from MedPage Today
medpagetoday.com — “SAN ANTONIO -- A combination of trastuzumab (Herceptin) and prophylactic cranial radiation to prevent brain metastases did not appear to cause cognitive dysfunction among metastatic breast cancer pati” View full resource at medpagetoday.com
Most Recently Shared on December 12, 2010 at 8:13 pm By:
SABCS: No Cognitive Decline from Radiation to Prevent Brain Mets (CME/CE) http://bit.ly/f2SqyX
Medical News: SABCS: HER2-Targeted Drugs Not Equal in Breast CA - in Meeting Coverage, SABCS from MedPage Today
medpagetoday.com — “SAN ANTONIO -- For presurgical treatment of HER2-positive early breast cancer, lapatinib (Tykerb) doesn't measure up to standard trastuzumab (Herceptin), according to head-to-head trial results.” View full resource at medpagetoday.com
Most Recently Shared on December 11, 2010 at 6:11 pm By:
SABCS: HER2-Targeted Drugs Not Equal in Breast CA (CME/CE) http://bit.ly/hmCMgD
Medical News: SABCS: HER2-Targeted Drugs Not Equal in Breast CA - in Meeting Coverage, SABCS from MedPage Today
medpagetoday.com — “SAN ANTONIO -- For presurgical treatment of HER2-positive early breast cancer, lapatinib (Tykerb) doesn't measure up to standard trastuzumab (Herceptin), according to head-to-head trial results.” View full resource at medpagetoday.com
Most Recently Shared on December 11, 2010 at 6:15 pm By:
SABCS: HER2-Targeted Drugs Not Equal in Breast CA (CME/CE) http://bit.ly/gy9hDh
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
PhysOrg Health News
PhysOrg.com Health and Medicine News Stories
-
newswise
Newswise is where journalists choose, connect, and use smart news. Thom from Newswise tweets latest news, press releases, connecting PR and journalists
-
Thom Canalichio
Bringing you the Latest Newswise Medical content.
Advertisement
